A generic PBTK model implemented in the MCRA platform: Predictive performance and uses in risk assessment of chemicals.

Mixtures Physiologically-based ToxicoKinetic (PBTK) model Probabilistic model Risk assessment

Journal

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
ISSN: 1873-6351
Titre abrégé: Food Chem Toxicol
Pays: England
ID NLM: 8207483

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 24 02 2020
revised: 07 05 2020
accepted: 15 05 2020
pubmed: 31 5 2020
medline: 30 3 2021
entrez: 31 5 2020
Statut: ppublish

Résumé

Physiologically-based toxicokinetic (PBTK) models are important tools for in vitro to in vivo or inter-species extrapolations in health risk assessment of foodborne and non-foodborne chemicals. Here we present a generic PBTK model implemented in the EuroMix toolbox, MCRA 9 and predict internal kinetics of nine chemicals (three endocrine disrupters, three liver steatosis inducers, and three developmental toxicants), in data-rich and data-poor conditions, when increasingly complex levels of parametrization are applied. At the first stage, only QSAR models were used to determine substance-specific parameters, then some parameter values were refined by estimates from substance-specific or high-throughput in vitro experiments. At the last stage, elimination or absorption parameters were calibrated based on available in vivo kinetic data. The results illustrate that parametrization plays a capital role in the output of the PBTK model, as it can change how chemicals are prioritized based on internal concentration factors. In data-poor situations, estimates can be far from observed values. In many cases of chronic exposure, the PBTK model can be summarized by an external to internal dose factor, and interspecies concentration factors can be used to perform interspecies extrapolation. We finally discuss the implementation and use of the model in the MCRA risk assessment platform.

Identifiants

pubmed: 32473292
pii: S0278-6915(20)30330-6
doi: 10.1016/j.fct.2020.111440
pii:
doi:

Substances chimiques

Hazardous Substances 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111440

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Cleo Tebby (C)

INERIS, Unit Models for Ecotoxicology and Toxicology (METO), Verneuil-en-Halatte, France. Electronic address: cleo.tebby@ineris.fr.

Hilko van der Voet (H)

Wageningen University & Research, Biometris, Wageningen, Netherlands.

Georges de Sousa (G)

INRAE, Toxalim, France.

Emiel Rorije (E)

RIVM, Centre for Safety of Substances and Products, Department for Consumers and Product Safety, P.O. Box 1, 3720, BA Bilthoven, Netherlands.

Vikas Kumar (V)

URV, Universitat Rovira i Virgili, C/ Països Catalans, nº 26, 43007, Tarragona (Tarragona- Catalonia), Spain.

Waldo de Boer (W)

Wageningen University & Research, Biometris, Wageningen, Netherlands.

Johannes W Kruisselbrink (JW)

Wageningen University & Research, Biometris, Wageningen, Netherlands.

Frédéric Y Bois (FY)

INERIS, Unit Models for Ecotoxicology and Toxicology (METO), Verneuil-en-Halatte, France.

Moosa Faniband (M)

Division of Occupational and Environmental Medicine, Faculty of Medicine, Lund University, Sweden.

Angelo Moretto (A)

Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Italy.

Céline Brochot (C)

INERIS, Unit Models for Ecotoxicology and Toxicology (METO), Verneuil-en-Halatte, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH